Search - tctmd.com

Displaying 1 - 20 of 63

Sort: Relevancy | Date

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity

News Conference News European Congress on Obesity 2025

Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity

Michael O'Riordan

May 16, 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

News Conference News European Congress on Obesity 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

Plant-Derived Compound Shows Early Promise for Small AAAs

News Conference News CX Symposium 2025

Plant-Derived Compound Shows Early Promise for Small AAAs

April 25, 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

April 10, 2025

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

News Conference News AHA 2024

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

November 16, 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

August 30, 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Debating the Role of T-TEER in the Sickest Patients

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

AI Tools to Meet Every Need? The Future of Vascular Medicine

News Conference News ISET 2024

AI Tools to Meet Every Need? The Future of Vascular Medicine

February 02, 2024

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH: Heart-1

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

November 12, 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.